Protagonist Therapeutics (PTGX)
24.66
-1.04 (4.05%)
Upcoming Events
Latest Headlines
Form 4 Protagonist Therapeutics For: Apr 18 Filed by: Ali Asif
April 19, 2024 8:06 PM - SEC Filing
Turnstone Biologics Appoints William Waddill to its Board of Directors
April 16, 2024 9:00 AM - StreetInsider
Form PRE 14A Protagonist Therapeutics For: Jun 20
April 12, 2024 4:31 PM - SEC Filing
Form 4 Protagonist Therapeutics For: Apr 01 Filed by: PATEL DINESH V PH D
April 2, 2024 8:30 PM - SEC Filing
Form 144 Protagonist Therapeutics Filed by: PATEL DINESH V PH D
April 1, 2024 4:09 PM - SEC Filing
Form 4 Protagonist Therapeutics For: Mar 07 Filed by: SELICK HAROLD E
March 11, 2024 8:01 PM - SEC Filing
Form 4 Protagonist Therapeutics For: Mar 01 Filed by: PATEL DINESH V PH D
March 1, 2024 8:47 PM - SEC Filing
Form 4 Protagonist Therapeutics For: Mar 01 Filed by: Waddill William D.
March 1, 2024 8:46 PM - SEC Filing
Form 4 Protagonist Therapeutics For: Feb 29 Filed by: Ali Asif
March 1, 2024 8:46 PM - SEC Filing
Form 144 Protagonist Therapeutics Filed by: Ali Asif
March 1, 2024 8:28 PM - SEC Filing
Form 144 Protagonist Therapeutics Filed by: Waddill William D.
March 1, 2024 4:32 PM - SEC Filing
Form 144 Protagonist Therapeutics Filed by: PATEL DINESH V PH D
March 1, 2024 4:28 PM - SEC Filing
Form 144 Protagonist Therapeutics Filed by: Ali Asif
February 29, 2024 5:49 PM - SEC Filing
Form 4 Protagonist Therapeutics For: Feb 26 Filed by: PATEL DINESH V PH D
February 28, 2024 8:03 PM - SEC Filing
Form 4 Protagonist Therapeutics For: Feb 26 Filed by: Gupta Suneel
February 28, 2024 8:01 PM - SEC Filing
Protagonist Therapeutics (PTGX) PT Raised to $37 at JPMorgan
February 28, 2024 7:08 AM - StreetInsider
Protagonist Therapeutics (PTGX) Tops Q4 EPS by 58c
February 28, 2024 2:15 AM - StreetInsider
Form S-8 Protagonist Therapeutics
February 27, 2024 4:54 PM - SEC Filing
Form 10-K Protagonist Therapeutics For: Dec 31
February 27, 2024 4:44 PM - SEC Filing
Form 8-K Protagonist Therapeutics For: Feb 27
February 27, 2024 4:16 PM - SEC Filing
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 27, 2024 4:08 PM - StreetInsider
Protagonist Therapeutics (PTGX) announces positive Phase 2 REVIVE results published in NEJM
February 21, 2024 5:03 PM - StreetInsider
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
February 21, 2024 5:02 PM - StreetInsider
Form 4 Protagonist Therapeutics For: Feb 15 Filed by: PATEL DINESH V PH D
February 20, 2024 8:01 PM - SEC Filing
Protagonist Therapeutics Reports Granting of Inducement Awards
February 20, 2024 4:06 PM - StreetInsider
Form SC 13G/A Protagonist Therapeutics Filed by: CITADEL ADVISORS LLC
February 14, 2024 4:59 PM - SEC Filing
Form SC 13G/A Protagonist Therapeutics Filed by: BIOTECHNOLOGY VALUE FUND L P
February 14, 2024 9:32 AM - SEC Filing
Form SC 13G/A Protagonist Therapeutics Filed by: RTW INVESTMENTS, LP
February 14, 2024 7:48 AM - SEC Filing
Form SC 13G/A Protagonist Therapeutics Filed by: Point72 Asset Management, L.P.
February 14, 2024 7:15 AM - SEC Filing
Form SC 13G/A Protagonist Therapeutics Filed by: VANGUARD GROUP INC
February 13, 2024 5:18 PM - SEC Filing
Protagonist Therapeutics (PTGX) Reports Publication of Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113
February 7, 2024 5:03 PM - StreetInsider
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
February 7, 2024 5:02 PM - StreetInsider
Form SC 13G/A Protagonist Therapeutics Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
February 7, 2024 7:42 AM - SEC Filing
Form SC 13G/A Protagonist Therapeutics Filed by: Farallon Capital Partners, L.P.
February 2, 2024 9:20 AM - SEC Filing
Takeda (TAK) and Protagonist Therapeutics (PTGX) Enter Global License and Collaboration Agreement for Rusfertide
January 31, 2024 4:09 PM - StreetInsider
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
January 31, 2024 4:08 PM - StreetInsider
Form 8-K Protagonist Therapeutics For: Jan 31
January 31, 2024 4:05 PM - SEC Filing
Full Article List
